Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancerEric Van Cutsem, Geert D’Haens, J-Y Douillard et al.|British Journal of Cancer|2013Cited by 50
A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS resultsDavid Cunningham, Eric Van Cutsem, Rlc Wong et al.|Journal of Clinical Oncology|2008Cited by 29
Exaggeration of PFS by blinded, independent, central review (BICR)A Stone, Alvarez Sabin, Val Gebski et al.|Annals of Oncology|2018Cited by 27
Application of adaptive study designs: Phase II and III results from the cediranib (CED) HORIZON (HZ) II and III studies.D. Wilson, A Stone, Jane Robertson et al.|Journal of Clinical Oncology|2011Cited by 2